Company press releases
| Released | Company | Title | Industry | Topic |
|---|---|---|---|---|
| 21 Mar 2024 19:38 CET |
NYKODE THERAPEUTICS ASA | Nykode Therapeutics - Mandatory notification of acquisition of shares by primary insider | 20103010 Biotechnology | Mandatory notification of trade primary insiders |
| 21 Mar 2024 07:00 CET |
NYKODE THERAPEUTICS ASA | Nykode Therapeutics Announces Topline Conclusions Affirming Prolonged Clinical Benefits from Matured Survival Data in Phase 2 C-02 Trial in Advanced Cervical Cancer | 20103010 Biotechnology | Non-regulatory press releases |
| 19 Mar 2024 07:00 CET |
NYKODE THERAPEUTICS ASA | Nykode Therapeutics Announces Advances in the Inverse Vaccine Platform With the Potential to Treat Autoimmune Diseases | 20103010 Biotechnology | Non-regulatory press releases |
| 13 Mar 2024 14:57 CET |
NYKODE THERAPEUTICS ASA | Nykode Therapeutics - Mandatory notification of acquisition of shares by primary insider | 20103010 Biotechnology | Mandatory notification of trade primary insiders |
| 08 Mar 2024 16:16 CET |
NYKODE THERAPEUTICS ASA | Nykode Therapeutics - Mandatory notification of acquisition of shares by primary insider | 20103010 Biotechnology | Mandatory notification of trade primary insiders |
| 08 Mar 2024 13:31 CET |
NYKODE THERAPEUTICS ASA | Nykode Therapeutics - Mandatory notification of acquisition of shares by primary insider | 20103010 Biotechnology | Mandatory notification of trade primary insiders |
| 04 Mar 2024 13:11 CET |
NYKODE THERAPEUTICS ASA | Nykode Therapeutics - Mandatory notification of acquisition of shares by primary insider | 20103010 Biotechnology | Mandatory notification of trade primary insiders |
| 29 Feb 2024 16:27 CET |
NYKODE THERAPEUTICS ASA | Nykode Therapeutics - Mandatory notification of acquisition of shares by primary insider | 20103010 Biotechnology | Mandatory notification of trade primary insiders |
| 28 Feb 2024 07:00 CET |
NYKODE THERAPEUTICS ASA | Nykode Therapeutics - Quarterly report Q4 2023 | 20103010 Biotechnology | Half yearly financial reports and audit reports/limited reviews |
| 22 Feb 2024 07:00 CET |
NYKODE THERAPEUTICS ASA | Nykode Therapeutics – invitation to Q4 2023 financial results presentation | 20103010 Biotechnology | Non-regulatory press releases |
| 19 Dec 2023 07:00 CET |
NYKODE THERAPEUTICS ASA | Nykode Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference | 20103010 Biotechnology | Non-regulatory press releases |
| 18 Dec 2023 21:19 CET |
NYKODE THERAPEUTICS ASA | Financial calendar | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 14 Dec 2023 07:00 CET |
NYKODE THERAPEUTICS ASA | Nykode Therapeutics Announces Expansion of Oncology Pipeline Aiming to Reduce the Burden of Colorectal Cancer | 20103010 Biotechnology | Non-regulatory press releases |
| 07 Dec 2023 18:00 CET |
NYKODE THERAPEUTICS ASA | Nykode Therapeutics - Share capital increase from exercise of warrants | 20103010 Biotechnology | Total number of voting rights and capital |
| 28 Nov 2023 10:49 CET |
NYKODE THERAPEUTICS ASA | Nykode Therapeutics - Share capital increase from exercise of warrants | 20103010 Biotechnology | Total number of voting rights and capital |
| 24 Nov 2023 18:20 CET |
NYKODE THERAPEUTICS ASA | Nykode Therapeutics – Primary insider transaction | 20103010 Biotechnology | Mandatory notification of trade primary insiders |
| 15 Nov 2023 07:00 CET |
NYKODE THERAPEUTICS ASA | Nykode Therapeutics - Quarterly report Q3 2023 | 20103010 Biotechnology | Half yearly financial reports and audit reports/limited reviews |
| 10 Nov 2023 17:13 CET |
NYKODE THERAPEUTICS ASA | Nykode Therapeutics - Share capital increase from exercise of warrants | 20103010 Biotechnology | Total number of voting rights and capital |
| 09 Nov 2023 08:30 CET |
NYKODE THERAPEUTICS ASA | Nykode Therapeutics – invitation to Q3 2023 financial results presentation | 20103010 Biotechnology | Non-regulatory press releases |
| 07 Nov 2023 08:30 CET |
NYKODE THERAPEUTICS ASA | Nykode Therapeutics to Present at Jefferies Healthcare Conference | 20103010 Biotechnology | Non-regulatory press releases |
| 31 Oct 2023 15:30 CET |
NYKODE THERAPEUTICS ASA | Nykode Therapeutics - Mandatory notification of acquisition of shares by primary insider | 20103010 Biotechnology | Mandatory notification of trade primary insiders |
| 31 Oct 2023 14:41 CET |
NYKODE THERAPEUTICS ASA | Disclosure of shareholding | 20103010 Biotechnology | Major shareholding notifications |
| 31 Oct 2023 09:16 CET |
NYKODE THERAPEUTICS ASA | Nykode Therapeutics ASA – New Share Capital Registered | 20103010 Biotechnology | Total number of voting rights and capital |
| 30 Oct 2023 23:29 CET |
NYKODE THERAPEUTICS ASA | Nykode Therapeutics ASA – Subsequent Offering Cancelled | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 27 Oct 2023 16:15 CEST |
NYKODE THERAPEUTICS ASA | Nykode Therapeutics - Mandatory notification of acquisition of shares by primary insider | 20103010 Biotechnology | Mandatory notification of trade primary insiders |
| 25 Oct 2023 17:22 CEST |
NYKODE THERAPEUTICS ASA | Nykode Therapeutics - Mandatory notification of trade by closely associated party of a primary Insider | 20103010 Biotechnology | Mandatory notification of trade primary insiders |
| 25 Oct 2023 15:32 CEST |
NYKODE THERAPEUTICS ASA | Nykode Therapeutics - Mandatory notification of trade by closely associated party of a primary Insider | 20103010 Biotechnology | Mandatory notification of trade primary insiders |
| 25 Oct 2023 14:33 CEST |
NYKODE THERAPEUTICS ASA | Disclosure of shareholding | 20103010 Biotechnology | Major shareholding notifications |
| 25 Oct 2023 08:15 CEST |
NYKODE THERAPEUTICS ASA | Disclosure of shareholding | 20103010 Biotechnology | Major shareholding notifications |
| 25 Oct 2023 02:05 CEST |
NYKODE THERAPEUTICS ASA | Nykode Therapeutics ASA – Share Lending by Closely Associated Parties of a Primary Insider | 20103010 Biotechnology | Mandatory notification of trade primary insiders |